Compare Docusign Inc (DOCU) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs Nuwellis Inc — how do they compare? Docusign Inc trades at $49.52 (market cap $9.43B), while Nuwellis Inc trades at $3.16 (market cap $1.17M). The key difference: Docusign Inc is far larger — about 8059.8× Nuwellis Inc's market cap, and Docusign Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| DOCU | NUWE | |
|---|---|---|
Market Cap | $9.43B | $1.17M |
Sector | Technology | Technology |
52-Week High | $85.01 | $558.26 |
52-Week Low | $41.75 | $2.80 |
Enterprise Value | $8.80B | -$636.97K |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $49.87, up 1.4% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals with revenue growth to $2.98B in 2025 and net income of $1.07B, supported by consistent earnings beats. Recent partnerships with Perplexity and Slack highlight innovation in agreement management, while analyst sentiment remains mixed with a $55.40 consensus target.
Outlook is cautiously optimistic given solid profitability and strategic initiatives, but risks include pricing pressure and sector volatility. The stock presents a growth opportunity if execution continues, though investor patience is required amid competitive and macroeconomic headwinds.
NUWE trades at $2.80, down 7.89% in the last session, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025 despite $8.27M revenue, reflecting negative profit margins and cash flow challenges. Recent news highlights expansion in pediatric care and a $6M public offering closed in June 2026, alongside a CEO transition to Mike McCormick effective June 30, 2026.
Outlook remains high-risk due to persistent losses and cash burn, though analyst consensus is split evenly between Buy and Hold. Key risks include execution in revenue growth and reliance on financing. Upside depends on successful commercialization of Aquadex therapy and FDA label expansion for pediatric patients.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
